Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4399 - Soft tissue sarcomas (STS) in elder patients: No impact of age on overall survival (OS) in an unselected cohort.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Geriatric Oncology

Tumour Site

Soft Tissue Sarcomas

Presenters

Jose Alejandro Perez Fidalgo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

J.A. Perez Fidalgo1, A. Lopez2, V. Gambardella3, S. Navarro4, A. Iranzo5, N. Diaz Fernandez2, P. Tolosa6, A. Silvestre7, E. Iriarte Moncho2, M.C. Garcia Mora8, A. De la Paz2, J.J. Soler9, A. Cervantes1

Author affiliations

  • 1 Medical Oncology, Hospital Clinico Universitario de Valencia. INCLIVA. CIBERONC Spain, 46010 - Valencia/ES
  • 2 Medical Oncology, Hospital San Juan, Alicante/ES
  • 3 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 4 Pathology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 5 Medical Oncology, Hospital Clinico Universitario de Valencia - INCLIVA, 46010 - Valencia/ES
  • 6 Medical Oncology, Hospital Clinico Universitario de Valencia. INCLIVA., 46010 - Valencia/ES
  • 7 Orthopedic Surgery, Hospital Clinico Universitario de Valencia. INCLIVA. CIBERONC Spain, 46010 - Valencia/ES
  • 8 Radiotherapy, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 9 Radiology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
More

Resources

Abstract 4399

Background

A recent analysis of 12 trials in first line showed similar outcomes for elder vs younger patients. Nevertheless these results might be due to a selection bias. The aim of our study was to assess whether elder patients (pts) (>60 years) had the same outcomes than younger (<60 years) in an unselected population of STS stage I-IV.

Methods

A retrospective analysis of pts diagnosed with STS stages I-IV at two institutions between 2000 and 2015 was performed. GIST and other indolent STS such us low-grade stromal sarcoma tumors, cutaneous Kaposi Sarcoma, Desmoid tumors and dermatofibrosarcoma protuberans were excluded. Demographic, clinical and pathological variables were obtained from the medical charts. Overall survival (OS) was calculated according to the date of death by any cause or lost of follow-up.

Results

115 pts, men/women 59/56 median age of 54.6 years (16.6-82.62) were included. 71 pts (61.7%) were <60 years (younger) and 44 (38.3%) were >60 years (older). Most frequent subtypes were liposarcoma (16.5%), leiomyosarcoma (14.8%) and undifferentiated sarcoma (9,6%). Most frequent sites were lower extremity (27.8%) , retroperitoneum (13.9%) and thorax (13.0%). TNM Stage (or FIGO in endometrial origin) were stage I-II (53%), III (38%) and IV (19%). 98 pts were operated of the primary tumor (Resection was R0 in 53, R1 in 30 and R2 in 4, in 11 data was missed). 37 pts (32.2%) received anthracyclines in any line (31 in younger and 6 in older pts). 68 pts (59.1%) had a local or systemic relapse. 53 pts died (46.1%). There were no differences by age group on stage, grade and radicality of surgery (chi squares p = 0.52, 0.48 and 0.47 respectively). Nevertheless elder patients were less likely to receive anthracycline-based therapy (RR 0.33 95%IC 0.16-0.72, p = 0.001). Grade and stage were significant prognostic factors for OS: median OS 104.4 m for Stage I-III vs 14.7 m Stage IV, p < 0.0001 and 146 m for low (grade 1-2) vs 49.1 m for high grade (grade 3) p = 0.0025, respectively. Age group had no effect on median OS (74.4 months for younger and 78.9 months for older log Rank p = 0.13).

Conclusions

Despite significant undertreatment with anthracycline regimens, elderly patients do not have worse survival outcomes in this exploratory analysis of an unselected population.

Clinical trial identification

Legal entity responsible for the study

Hospital Clinico Universitario de Valencia. INCLIVA.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.